REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER

• US 20190314323A1
• Filed: 02/04/2019
• Published: 10/17/2019
• Est. Priority Date: 02/16/2012
• Status: Abandoned Application

• Current Assignee: Akeso Biomedical, Inc.
• Original Assignee: Akeso Biomedical, Inc.
• Inventors: Mahdavi, Jafar, Ala'Aldeen, Dlawer
• Application Number:
  US16/266,946
• Publication Number:
  US 20190314323A1
• Time in Patent Office: Days
• CPC Class Codes: A23K 20/111 Aromatic compounds
• CPC Class Codes: A23K 20/142 Amino acids; Derivatives thereof
• CPC Class Codes: A23K 50/75 for poultry
• CPC Class Codes: A61K 31/132 having two or more amino groups, e.g. spermidine, putrescine
• CPC Class Codes: A61K 31/136 having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• CPC Class Codes: A61K 31/164 of a carboxylic acid with an aminoalcohol, e.g. ceramides
• CPC Class Codes: A61K 31/191 having two or more hydroxy groups, e.g. gluconic acid
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/661 Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
• CPC Class Codes: A61K 31/7008 Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C12Q 1/18 Testing for antimicrobial activity of a material
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of from one animal to another.

Claims

1-29. -29. (canceled)

30. A composition comprising ferric quinate, complex of a 3,4-dihydroxyphenylalanine or tyrosine with Fe III or a compound with a structure selected from the group consisting of:

31. The composition of claim 30, wherein the composition is an animal feed, a food supplement, drinking water or drinking water supplement.

32. The composition of claim 30, wherein the compound is present in a concentration range between 34 to 340 μ

M.

33. The composition of claim 30, wherein the compound specifically binds to at least one amino acid residue selected from the group consisting of Arg^3S2, Thr²⁶⁸, Lys²⁷⁸, Lys³⁸⁵, Asn²⁵⁸, Leu²⁹⁰, Tyr²⁹⁴, Phe³⁹⁵, Ile³³⁷, Arg³⁸¹, Asp²⁶¹, and Ser³⁹⁷ of MOMP (SEQ ID NO:

1).

34. The composition of claim 33, wherein the compound specifically binds to at least amino acid residue Thr²⁶⁸ of MOMP (SEQ ID NO.1).

35. The composition of claim 30, wherein the compound reduces the campylobacter colony forming units in the gastrointestinal tract of the animal by at least 50%.

36. The composition of claim 30, the Campylobacter is Campylobacter jejuni or Campylobacter coli.

37. The composition of claim 30, wherein the compound is a complex of Fe III with 3,4-dihydroxyphenylalanine or tyrosine.

38. The composition of claim 30, wherein the compound is ferric quinate.

39. A method for treating or reducing Campylobacter colonization in an animal subject comprising administering to the animal, the composition of claim 30.

40. The method of claim 39, wherein the Campylobacter is Campylobacter jejuni or Campylobacter Coli.

41. The method of claim 39, wherein the compound is administered orally.

42. The method of claim 39, wherein the compound specifically binds to at least one amino acid residue selected from the group consisting of Arg^3S2 Thr²⁶⁸, Lys²⁷⁸, Lys³⁸⁵, Asn²⁵⁸, Leu²⁹⁰, Tyr²⁹⁴, Phe³⁹⁵, Ile³³⁷, Arg³⁸¹, Asp²⁶¹, and Ser³⁹⁷ of MOMP (SEQ ID NO:

1).

43. The method of claim 39, wherein the compound specifically binds to at least amino acid residue Thr²⁶⁸ of MOMP (SEQ ID NO.1).

44. The method of claim 39, wherein the compound reduces the campylobacter colony forming units in the gastrointestinal tract of the animal by at least 50%.

45. The method of claim 39, wherein the compound is a complex of Fe III with 3,4-dihydroxyphenylalanine or tyrosine.

46. The method of claim 39, wherein the compound is ferric quinate.

47. The method of claim 39, wherein the animal is selected from the group consisting of poultry, cattle, sheep, pigs, goats and deer.

48. The method of claim 47, wherein the poultry is selected from the group consisting of chickens, geese, turkeys and ducks.

49. The composition of claim 30, wherein the composition is a foodstuff or a food for human consumption selected from the group consisting of a fresh meat product, a processed meat product, a chilled meat product, a frozen meat product or a cooked meat product, wherein the meat product is selected from the group consisting of beef, lamb, pork, duck, chicken, goose, turkey, and rabbit.